

Supporting information

**Electronic strain effect on Eu(III) complexes for enhanced circularly
polarized luminescence**

Makoto Tsurui,^a Yuichi Kitagawa,^{b,c} Koji Fushimi,^b Masayuki Gon,^d Kazuo Tanaka,^d and Yasuchika Hasegawa^{*b,c}


^a Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13, Nishi 8, Kita-ku, Sapporo 060-8628, Japan

^b Faculty of Engineering, Kita 13, Nishi 8, Kita-ku Sapporo, 060-8628, Japan.

^c Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Kita 21, Nishi 10, Kita-ku, Sapporo 001-0021, Japan

^d Graduate School of Engineering, Kyoto University, Kyoto daigaku-katsura, Nishikyo-ku, Kyoto 615-8510, Japan

Scheme S1 Synthetic scheme of Eu(III) complexes.



Preparation of (*S,S*)-2,3-Bis(*tert*-butylmethylphosphineoxide)quinoxaline ((*S,S*)-B2QPO): (*S,S*)-B2QPO was synthesized by the same procedure as described for the (*R,R*)-B2QPO. Yield: 61%. ¹H NMR (400 MHz, CDCl₃/TMS, 25°C): δ = 8.14 (dd, J = 6.4, 3.7 Hz, 2H), 7.92 (dd, J = 6.4, 3.7 Hz, 2H), 2.11 (d, J = 12.3 Hz, 6H), 1.43 (d, J = 14.6 Hz, 18H) ppm. IR (ATR): ν = 2822-2999 (m, C-H), 1151 (s, P=O) cm⁻¹. APCI-MS (*m/z*): calcd for C₁₈H₂₉N₂O₂P₂ [*m + H*]⁺: 367.2, found 367.2.

Preparation of (*S*)-2-*tert*-butylmethylphosphineoxide-3-(di-*tert*-butylphosphineoxide)quinoxaline ((*S*)-B3QPO): (*S*)-B3QPO was synthesized by the same procedure as described for the (*R*)-B3QPO. Yield: 82%. ¹H NMR (400 MHz, CDCl₃/TMS, 25°C): δ = 8.23-8.09 (m, 2H), 7.98-7.85 (m, 2H), 2.24 (d, J = 12.8 Hz, 3H), 1.55-1.25 (m, 27H) ppm. IR (ATR): ν = 2861-2967 (m, C-H), 1161 (s, P=O) cm⁻¹. APCI-MS (*m/z*): calcd for C₂₁H₃₅N₂O₂P₂ [*m + H*]⁺: 409.2, found 409.2.

Preparation of [Eu(hfa)₃(H₂O)₂] (hfa: hexafluoroacetylacetonato): [Eu(hfa)₃(H₂O)₂] was prepared with the procedure described in previous report¹.

Preparation of [Eu(hfa)₃((S,S)-B2QPO)]: [Eu(hfa)₃((S,S)-B2QPO)] was synthesized by the same procedure as described for the [Eu(hfa)₃((R,R)-B2QPO)]. Yield: 45%. ESI-Mass (*m/z*): [M-hfa]⁺ calcd. for C₂₈H₃₀EuF₁₂N₂O₆P₂, 933.06; found, 933.10. Anal. calcd. for C₃₃H₃₁EuF₁₈N₂O₈P₂, C 34.78, H 2.74, N 2.46; found, C 34.36, H 2.53, N 2.29%. FT-IR (ATR) : 1652 (st, C=O), 1252 (st, C-F), 1141 (st, P=O) cm⁻¹.

Preparation of [Eu(hfa)₃((S)-B3QPO)]: [Eu(hfa)₃((S)-B3QPO)] was synthesized by the same procedure as described for the [Eu(hfa)₃((R)-B3QPO)]. Yield: 42%. ESI-Mass (*m/z*): [M-hfa]⁺ calcd. for C₃₁H₃₆EuF₁₂N₂O₆P₂, 975.11; found, 975.11. Anal. calcd. for C₃₆H₃₇EuF₁₈N₂O₈P₂, C 36.59, H 3.16, N 2.37; found, C 36.55, H 2.99, N 2.28%. FT-IR (ATR) : 1650 (st, C=O), 1251 (st, C-F), 1140 (st, P=O) cm⁻¹.

Preparation of [Gd(hfa)₃(H₂O)₂]: [Gd(hfa)₃(H₂O)₂] was synthesized by the same procedure as described for the [Eu(hfa)₃(H₂O)₂].

Preparation of [Gd(hfa)₃((R,R)-B2QPO)]: [Gd(hfa)₃((R,R)-B2QPO)] was synthesized by the same procedure as described for the [Eu(hfa)₃((R,R)-B2QPO)]. Yield 45%. ESI-Mass (*m/z*): [M-hfa]⁺ calcd. for C₂₈H₃₀GdF₁₂N₂O₆P₂, 938.06; found, 938.06. Anal. calcd. for C₃₃H₃₁GdF₁₈N₂O₈P₂, C 34.62, H 2.73, N 2.45; found, C 34.34, H 2.56, N 2.34%. FT-IR (ATR) : 1653 (st, C=O), 1253 (st, C-F), 1139 (st, P=O) cm⁻¹.

Preparation of [Gd(hfa)₃((R)-B3QPO)]: [Gd(hfa)₃((R)-B3QPO)] was synthesized by the same procedure as described for the [Eu(hfa)₃((R)-B3QPO)]. Yield 43%. ESI-Mass (*m/z*): [M-hfa]⁺ calcd. for C₃₁H₃₆GdF₁₂N₂O₆P₂, 980.11; found, 980.11. Anal. calcd. for

$C_{36}H_{37}GdF_{18}N_2O_8P_2$, C 36.43, H 3.14, N 2.36; found, C 36.34, H 3.00, N 2.29%. FT-IR
(ATR) : 1650 (st, C=O), 1250 (st, C-F), 1137 (st, P=O) cm^{-1} .

Table S1. X-ray crystal data of Eu(III) complexes

	[Eu(hfa)((R,R)-B2QPO)]	[Eu(hfa)((S,S)-B2QPO)]	[Eu(hfa) ₃ ((R)-B3QPO)]	[Eu(hfa) ₃ ((S)-B3QPO)]
Chemical formula	C ₃₃ H ₃₁ EuF ₁₈ N ₂ O ₈ P ₂	C ₃₃ H ₃₁ EuF ₁₈ N ₂ O ₈ P ₂	C ₃₆ H ₃₇ EuF ₁₈ N ₂ O ₈ P ₂	C ₃₆ H ₃₇ EuN ₂ O ₈ F ₁₈ P ₂
Formula weight	1139.50	1139.50	1181.57	1181.57
Crystal system	monoclinic	monoclinic	monoclinic	monoclinic
Space group	P2 ₁ (#4)	P2 ₁ (#4)	P2 ₁ (#4)	P2 ₁ (#4)
<i>a</i> / Å	11.6631(2)	11.6679(3)	11.19040(10)	11.2020(2)
<i>b</i> / Å	19.2898(2)	19.2967(4)	20.5895(2)	20.6003(3)
<i>c</i> / Å	20.1981(2)	20.2075(4)	20.3663(2)	20.3840(4)
α / deg.	90	90	90	90
β / deg.	93.5450(10)	93.568(2)	99.7900(10)	99.687(2)
γ / deg.	90	90	90	90
Volume / Å ³	4535.45(10)	4540.94(18)	4624.16(8)	4636.83(14)
<i>Z</i>	4	4	4	4
Temperature / K	123.15	123.15	123.15	123.15
<i>d</i> _{calc} / g cm ⁻³	1.669	1.667	1.697	1.693
Radiation	MoKα ($\lambda = 0.71073$)			
Reflections collected	85714	108043	137245	108302
Goodness-of-fit on F ²	1.053	1.042	1.031	1.033
<i>R</i> ₁	0.0439	0.0418	0.0240	0.0303
<i>WR</i> ₂	0.1177	0.1141	0.0572	0.0711
Flack parameter	0.000(4)	-0.005(4)	-0.012(3)	0.000(4)

Table S2. X-ray crystal data of Gd(III) complexes

	Gd(hfa)(R,R-B2QPO)	Gd(hfa)(R-B3QPO)
Chemical formula	C ₃₃ H ₃₁ F ₁₈ GdN ₂ O ₈ P ₂	C ₃₆ H ₃₇ F ₁₈ GdN ₂ O ₈ P ₂
Formula weight	1144.79	1186.86
Crystal system	monoclinic	monoclinic
Space group	P2 ₁	P2 ₁ (#4)
<i>a</i> / Å	11.6565(2)	11.16540(10)
<i>b</i> / Å	19.2883(3)	20.5710(2)
<i>c</i> / Å	20.1991(3)	20.3672(2)
α / deg.	90	90
β / deg.	93.4630(10)	99.6950(10)
γ / deg.	90	90
Volume / Å ³	4533.15(12)	4611.20(8)
<i>Z</i>	4	4
Temperature / K	123.15	123.15
<i>d</i> _{calc} / g cm ⁻³	1.677	1.710
Radiation	MoKα (λ = 0.71073)	MoKα (λ = 0.71073)
Reflections collected	127032	119067
Goodness-of-fit on F ²	1.031	1.026
<i>R</i> ₁	0.0395	0.0212
<i>WR</i> ₂	0.1070	0.0512
Flack parameter	-0.006(3)	-0.007(2)




Figure S1. Simulated XRD patterns of i) $[\text{Eu}(\text{hfa})_3((R,R)\text{-B2QPO})]$, ii) $[\text{Gd}(\text{hfa})_3((R,R)\text{-B2QPO})]$, iii) $[\text{Eu}(\text{hfa})_3((R)\text{-B3QPO})]$, and iv) $[\text{Gd}(\text{hfa})_3((R)\text{-B3QPO})]$ from CIF files.

The absorption spectra of chiral phosphine oxide ligands, precursor complex ($[\text{Eu}(\text{hfa})_3(\text{H}_2\text{O})_2]$), and chiral Eu(III) complexes are shown in Figure S1. The absorption bands at 300-350 nm are attributed to $\pi-\pi^*$ transitions of hfa and phosphine oxide ligands. The bands at around 250 nm are attributed to the existing of phosphine oxide ligands.




Figure S2. UV-vis absorption spectra of (a) $[\text{Eu}(\text{hfa})_3((R,R)\text{-B2QPO})]$ ((i), red line), $[\text{Eu}(\text{hfa})_3(\text{H}_2\text{O})_2]$ ((ii), black line) and $(R,R)\text{-B2QPO}$ ((iii), blue line), (b) $[\text{Eu}(\text{hfa})_3((R)\text{-B3QPO})]$ ((iv), red line), $[\text{Eu}(\text{hfa})_3(\text{H}_2\text{O})_2]$ ((v), black line) and $(R)\text{-B3QPO}$ ((vi), blue line) in dichloromethane ($1.0 \times 10^{-4} \text{ M}$) at room temperature.






Figure S3. (a) ^{31}P and (b) ^{19}F NMR (400 MHz) spectra of ligands ($(R,R)\text{-B2QPO}$, $(R)\text{-B3QPO}$) and complexes ($[\text{Eu}(\text{hfa})_3((R,R)\text{-B2QPO})]$, $[\text{Eu}(\text{hfa})_3((R)\text{-B3QPO})]$).

[Al(hfa)₃(*R,R*)-B2QPO]



[Al(hfa)₃(*R*)-B3QPO]




Figure S4. Molecular orbitals of [Al(hfa)₃((*R,R*)-B2QPO)] and [Al(hfa)₃((*R*)-B3QPO)]

Table S3. Calculated HOMO, HOMO-1, and HOMO-2 energy levels of [Al(hfa)₃((*R,R*)-B2QPO)] and [Al(hfa)₃((*R*)-B3QPO)] obtained by DFT calculations.

Complex	Energy level / eV		
	HOMO	HOMO-1	HOMO-2
[Al(hfa) ₃ ((<i>R,R</i>)-B2QPO)]	-6.050	-6.173	-6.437
[Al(hfa) ₃ ((<i>R</i>)-B3QPO)]	-6.216	-6.259	-6.302

Reference

- 1 Y. Hasegawa, Y. Wada, S. Yanagida, H. Kawai, N. Yasuda and T. Nagamura, Polymer thin films containing Eu(III) complex as lanthanide lasing medium, *Appl. Phys. Lett.*, 2003, **83**, 3599–3601.